公司资料
Angion Biomedica 股价、新闻与催化剂
- 股票代码:
- ANGN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for ANGN.
公司概览
业务概览
Angion Biomedica was a development-stage biotech focused on kidney disease, inflammation, and organ-protection biology. Its story was built around a narrow set of programs trying to create value in hard-to-treat indications.
所在地与行业分类
Angion was headquartered in the United States and listed on NASDAQ. It sat in small-cap biotechnology with a translational medicine profile.
商业模式特征
The company depended on clinical progress, target validation, and capital management to keep programs moving. Investors typically focused on early readouts, pipeline prioritization, and whether the biology could support a durable asset.
生物医药行业定位
Angion occupied a classic small-cap biotech niche where a limited pipeline and limited runway made the stock highly sensitive to data and financing.
未来催化剂
- Angion Biomedica is a legacy / closeout story, with catalysts limited to any residual asset or corporate update. There is no active standalone pipeline driving the name.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。